Literature DB >> 22293788

[Prognostic marker profiles for risk of distant metastases in colorectal cancer].

J Neumann1, S Reu, T Kirchner.   

Abstract

In colorectal cancer (CRC) prognostic markers correlating with distant metastasis are of high clinical value. In recent years it could be demonstrated that sporadic CRC with microsatellite instability (MSI) exhibits a very low risk for distant spread. Within this group the medullary subtype represents a morphological prototype. In the new WHO classification other morphological variants, such as mucinous, signet ring cell, serrated, cribriform comedo type and solid-undifferentiated forms are graded according to their microsatellite status. The clinical value of BRAF mutations is also dependent on the microsatellite status. Recent data have shown an ambivalent prognostic impact of BRAF mutations. A BRAF mutation in combination with MSI is associated with a good prognosis, whereas a BRAF mutation in the background of microsatellite stability (MSS) indicates a very poor outcome. Based on the concept of migrating stem cells, combined high scores of CD133 and nuclear β-catenin expression can be additionally used as markers for a high risk of distant metastasis. Hence, an immunohistochemical algorithm can be defined by the combination of three markers (hMLH1, CD133 and β-catenin) which allows CRC with either a very high or a very low risk of distant spread to be identified.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293788     DOI: 10.1007/s00292-011-1543-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  27 in total

1.  A simple immunohistochemical algorithm predicts the risk of distant metastases in right-sided colon cancer.

Authors:  Jens Neumann; David Horst; Lydia Kriegl; Susanne Maatz; Jutta Engel; Andreas Jung; Thomas Kirchner
Journal:  Histopathology       Date:  2012-02       Impact factor: 5.087

2.  Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms.

Authors:  Jinru Shia; David S Klimstra; Khedoudja Nafa; Kenneth Offit; Jose G Guillem; Arnold J Markowitz; William L Gerald; Nathan A Ellis
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

Review 3.  Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression.

Authors:  Thomas Brabletz; Andreas Jung; Simone Spaderna; Falk Hlubek; Thomas Kirchner
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

4.  Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer.

Authors:  Lydia Kriegl; Jens Neumann; Michael Vieth; Florian R Greten; Simone Reu; Andreas Jung; Thomas Kirchner
Journal:  Mod Pathol       Date:  2011-03-18       Impact factor: 7.842

5.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Authors:  Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

6.  The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.

Authors:  David Horst; Silvio K Scheel; Sibylle Liebmann; Jens Neumann; Susanne Maatz; Thomas Kirchner; Andreas Jung
Journal:  J Pathol       Date:  2009-12       Impact factor: 7.996

7.  CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.

Authors:  David Horst; Lydia Kriegl; Jutta Engel; Andreas Jung; Thomas Kirchner
Journal:  Eur J Cancer       Date:  2009-05-04       Impact factor: 9.162

8.  [Development of molecular-pathologic entities of colorectal cancer].

Authors:  T Kirchner; S Reu
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

9.  Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Authors:  Sun Lee; Nam-Yun Cho; Minhee Choi; Eun J Yoo; Jung-Ho Kim; Gyeong H Kang
Journal:  Pathol Int       Date:  2008-02       Impact factor: 2.534

10.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.

Authors:  Jinru Shia
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

View more
  3 in total

Review 1.  [Molecular pathology of colorectal cancer].

Authors:  J H L Neumann; A Jung; T Kirchner
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

2.  Impact of reassessment of colonic hyperplastic polyps by expert GI pathologists.

Authors:  Guido Schachschal; Susanne Sehner; Matthias Choschzick; Daniela Aust; Lydia Brandl; Michael Vieth; Karl Wegscheider; Gustavo B Baretton; Thomas Kirchner; Guido Sauter; Thomas Rösch
Journal:  Int J Colorectal Dis       Date:  2016-02-04       Impact factor: 2.571

3.  Serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition.

Authors:  Simona Gurzu; Zoltan Szentirmay; Erika Toth; Tivadar Bara; Tivadar Bara; Ioan Jung
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.